Abstract:Pseudomonas aeruginosa is an important conditioned pathogen with a variety of virulence factors in the clinic. It can cause a wide variety of acute and chronic infections. One of the most important of virulence factors is the type III secretion system (T3SS) that translocate effector proteins from the bacterium into the host cells to causes the pathological changes of host cells, and to escape degradation of immune cells. Research T3SS could help to clarify the pathogenesis of Pseudomonas aeruginosa, and more importantly, to provide new ideals for clinical treatment and drug development.
鞠晓红,李瑶,王月华,冯宪敏. 铜绿假单胞菌Ⅲ型分泌系统的研究进展[J]. 中国人兽共患病学报, 2015, 31(1): 83-87.
JU Xiao-hong,LI Yao,WANG Yue-hua,FENG Xian-min. Research progress of type III secretion system in Pseudomonas aeruginosa. Chinese Journal of Zoonoses, 2015, 31(1): 83-87.
[1]Davis PB. Cystic fibrosis since 1938[J]. Am J Respir Crit Care Med, 2006, 173(5):475-482. [2]Matz C, Moreno AM, Alhede M, et al. Pseudomonas aeruginosa uses type III secretion system to kill biofilm-associated amoebae[J].ISME J, 2008, 2(8):843-852. [3]Abd H, Wretlind B, Saeed A, et al. Pseudomonas aeruginosa utilises its type III secretion system to kill the free-living amoeba Acanthamoeba castellanii[J]. J Eukaryot Microbiol, 2008, 55(3):235-243. [4]Preston GM. Metropolitan microbes: type III secretion in multihost symbionts[J]. Cell Host Microbe, 2007, 2(5):291-294. [5]Galle1 M, Carpentier I, Beyaert R, et al. Structure and function of the Type III Secretion System of Pseudomonas aeruginosa[J]. CurrProtein Peptide Sci, 2012, 13(8):831-842. [6]Sundin C, Thelaus J, Broms JE, et al. Polarisation of type III translocation by Pseudomonas aeruginosa requires PcrG PcrV and PopN[J]. Microb Pathog, 2004, 37(6):313-322. [7]Lei CB, Chao Y, Sun XH, et al. Detection of virulence genes in Pseudomonas aeruginosa and its clinical significance[J]. Clin J Clin Lab Sci, 2011, 29(4):301-303. (in Chinese) 类承斌, 晁艳, 孙相红, 等.铜绿假单胞菌毒力基因检测及临床意义[J].临床检验杂志, 2011, 29(4):301-303. [8]Diaz MR, King JM, Yahr TL. Intrinsic and extrinsic regulation of Type III secretion gene expression in Pseudomonas aeruginosa[J]. Front Microbiol, 2011, 2(4):89-99. [9]Bernhards RC, Marsden AE, Esher SK, et al. Self-trimerization of ExsD limits inhibition of the Pseudomonas aeruginosa transcriptional activator ExsA in vitro[J]. FEBS J, 2013, 280(4):1084-1094. [10]Cisz M, Lee PC, Rietsch A. ExoS controls the cell contactmediated switch to effector secretion in Pseudomonas aeruginosa[J]. J Bacteriol, 2008, 190(8):2726-2738. [11]Chatterjee S, Chaudhury S, Andrew C, et al. Structure and biophysics of type III secretion in bacteria[J]. Biochemistry, 2013, 52(15):2508-2517. [12]Heimer SR, Evans DJ, Stern ME, et al. Pseudomonas aeruginosa utilizes the type III secreted toxin ExoS to avoid acidified compartments within epithelial cells[J]. PLoS One, 2013, 8(9):e73111-113. [13]Hritonenko V, Evans DJ, Fleiszig SM. Translocon-independent intracellular replication by Pseudomonas aeruginosa requires the ADP-ribosylation domain of ExoS[J]. Microbes Infect, 2012, 14(15):1366-1373. [14]Angus AA, Evans DJ, Barbieri JT, et al. The ADP-ribosylation domain of Pseudomonas aeruginosa ExoS is required for membrane bleb niche formation and bacterial survival within epithelial cells[J]. Infect Immun, 2010, 48(11):4500-4510. [15]Shaver CM, Hauser AR. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung[J]. Infect Immun, 2004, 72(12):6969-6977. [16]Sato H, Frank DW, Hillard CJ, et al. The mechanism of action of the Pseudomonas aeruginosa encoded type III cytotoxin, ExoU[J]. EMBO J, 2003, 22(12):2959-2969. [17]Diaz MH, Hauser AR. Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytic cells during acute pneumonia[J]. Infect Immun, 2010, 78(4):1447-1456. [18]Diaz MH, Shaver CM, King JD, et al. Pseudomonas aeruginosa induces localized immunosuppression during pneumonia[J]. Infect Immun, 2008, 76(10):4414 4421. [19]Heather A, Howell A, Latania K, et al. Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia[J].Mbio, 2013, 4(2):e00032-13. [20]Hu H, Harmer C, Anuj S, et al. Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening[J]. Clin Microbiol Infect, 2013, 19(3):266-272. [21]Galle M, Jin S, Bogaert P, et al. The Pseudomonas aeruginosa type III secretion system has an exotoxin S/T/Y independent pathogenic role during acute lung infection[J]. PLoS One, 2012, 7(7):e41547-415478. [22]Shen EP, Tsay RY, Chia JS, et al. The role of type III secretion system and lens material on adhesion of Pseudomonas aeruginosa to contact lenses[J]. Invest Ophthalmol Vis Sci, 2012, 53(20):6416-6426. [23]Zhang CF, Wu XG, Li Y, et al. Synthesis and bioactivity of novel inhibitors for type III secretion system of Pseudomonas aeruginosa PAO1[J]. Chin J Organic Chem, 2013, 4(8):1-13. (in Chinese) 张成芳, 吴小刚, 李燕, 等.铜绿假单胞菌PAO1 Ⅲ型分泌系统新型抑制剂的合成和生物活性研究[J].有机化学, 2013, 4(8):1-13. [24]Arnoldo A, Curak J, Kittanakom S, et al. Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen[J]. PLoS Genet, 2008, 4(2):el000005-1000013. [25]Yamazaki A, Li J, Zeng Q, et al. Derivatives of plant phenolic compound effect the type III secretion system of Pseudomonas aeruginosa via a GacS/GacA two-component signal transduction system[J]. Antimicrob Agents Chemother, 2012, 56(1):36-43. [26]Baer M, Sawa T, Flynn P, et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity[J]. Infect Immun, 2009, 77(3):1083-1090.